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TECHNICAL NOTE
Binding of soluble immune complexes to human glomerular
complement receptors
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Department of Medicine, State University of Liege, Liege, Belgium, and Department of Nephrology, Bellevue Hospital,
Saint-Etienne, France
It generally is admitted that the glomerular depo-
sition of antigen-antibody complexes merely results
from their trapping by the glomerular capillary bed
during the ultrafiltration process [1]. The presence
of glomerular complement receptors (GCR) 12-81 on
the epithelial [3, 8] or mesangial cells [6, 71 suggests
that another mechanism leading to the glomerular
localization of complement-bearing immune com-
plexes could be their selective interaction with the
GCR. To study the binding of immune complexes to
the GCR in vitro, we determined the normal GCR
binding activity with a technique recently described
by Gelfand et al [9]. After the binding conditions
were standardized, we studied the GCR binding
activity in the presence of increasing amounts of
aggregated immunoglobulins or of DNA-anti-DNA
complexes. The GCR binding activity then was
measured in the presence of serum samples from
patients presenting with presumed immune com-
plex-mediated glomerular diseases. In those serum
samples where the GCR binding activity was signifi-
cantly reduced, the physicochemical and immuno-
chemical properties of the causative material were
characterized further. Finally, correlations were
made between the GCR binding activity and the Clq
binding test [10].
Methods
Salmonellae typhi, type 0901, were grown in 200
ml of Oxoid no. 2 broth (Oxoid Ltd, London) at
370 C on a shaking tray overnight. They were heat
killed (600 C for 20 mm), washed, and resuspended
in 5 ml of phosphate-buffered saline (PBS). For flu-
orescein conjugation, we used a modification of the
method of Gelfand et a! [9]. One milliliter of the
Sal. typhi suspension was diluted five times in PBS
and stirred for 45 mm at room temperature with 1
mg of fluorescein isothiocyanate (FITC) dissolved
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in 2 ml of 0.1 M disodium acid phosphate buffer (pH,
9.5). After the preparation was washed with 0.15
M sodium chloride solution, excess FITC was re-
moved, and the sedimented Sal. typhi were resus-
pended to 2 ml in PBS. They were then divided into
0.1-mi aliquots and stored at —70°C until use. For
the preparation of FITC-Sal. typhi bearing C3b, 0.1
ml of the bacterial suspension was incubated with
an equal volume of fresh normal human serum
(NHS) as a source of complement (C) for 15 mm at
37° C. The Sal. typhi were then washed three times
with 2 ml of veronal-buffered (5mM) saline (VBS;
pH, 7.4) containing 0.1% gelatin, 1.5 x l0 M cal-
cium chloride and 5 x 10 M magnesium chloride
[11]. After the last washing, the suspension was
centrifuged at x700g for 15 mm, the supernatant
was discarded, and the FITC Sal. typhi bearing C3b
were resuspended in :2 ml of Hank's balanced salt
solution. To demonstrate the presence of C3 on the
Sal. typhi, we performed similar experiments us-
ing unlabeled Sal. typhi incubated either with fresh
or heat-inactivated NHS (56° C for 30 mm), and
treated thereafter with goat fluoresceinated anti-
human C3 antiserum. In these conditions, only the
Sal. typhi incubated with the fresh NHS were fluo-
rescent under the ultraviolet microscope.
Three human kidneys, devoid of histologic le-
sions, were obtained at surgery; they always were
unused cadaver donor kidneys. Kidney specimens
were stored at —70° C for several months until use.
They were cut in a cryostat at 5-is thickness and air
dried, according to the method of Shin et al [31. The
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sections were incubated with 50 .d of the FITC Sal.
typhi suspension in a moist chamber at room tem-
perature for 15 mm, They were washed three times
with PBS (pH, 7.2) and were examined by either
phase contrast or fluorescent microscopy, with a
Leitz light microscope equipped with an HBO-50
mercury lamp. The number of FTTC Sal. typhi
bound to five glomeruli exhibiting comparable di-
ameters was recorded independently by two ob-
servers (magnification, x400), and then the mean
value 1 SD was calculated. These conditions were
chosen on the basis of preliminary experiments
demonstrating that duplicate countings of bacteria
in a higher number of glomeruli did not improve
markedly the results. Control experiments were
performed with FITC Sal. typhi treated with heat-
inactivated NHS.
As a model for immune complexes, we first used
aggregated human gamma-globulins (agg. HGG).
The agg. HGG were obtained by heating normal hu-
man Cohn fraction II (Hyland, Travenol Laborato-
ries, Belgium) at 63° C for 20 mm at a concentration
of 6 mg/mI in 0.15 M sodium chloride. This prepara-
tion was centrifuged for 15 mm at x1,500g and
stored at —70° C. The agg. HGG were used at the
concentration of 1 mg/mI, the protein content being
measured with the method of Lowry et al [12] with
bovine serum albumin as a standard. Purified hu-
man anti-DNA antibodies and double-stranded
DNA (DS-DNA) were a gift from Dr. G. Fournië
(Toulouse). Five hundred micrograms of anti-DNA
antibodies contained in 250 pJ of PBS were mixed
with 200 g of DS-DNA contained in 200 d of bo-
rate buffer (ionic strength, 0.1; pH, 8.4) for 1 hour at
37° C and for 18 hours at 4° C. At that time, the
DNA-anti-DNA complexes were precipitated with
the method of Wold et al [13]. The mixture was cen-
trifuged at x 1 ,000g for 30 mm, and the precipitate
was washed three times with 2 ml of VBS. The last
pellet was resuspended in 500 d of VBS, and its
protein content was measured by the method of
Lowry et al [12]. The size of the immune complexes
was evaluated by ultracentrifugation in linear su-
crose gradients, according to the method of Natali
and Tan [14]. For the determination of the GCR
binding activity in the presence of immune com-
plexes, 10 to 100 .tg of agg. HGG or of DNA-anti-
DNA complexes were first incubated for 15 mm at
37° C with I ml of fresh NHS, after which 50 tl
were put onto the normal human kidney sections in
a moist chamber at room temperature for 15 mm. At
that time, 50 l of the FITC Sal. typhi bearing C3b
suspension (013 at 540 m, 1,8) were added. After
another 15-mm incubation period, the kidney sec-
tions were washed, and the number of Sal. typhi per
glomerulus was counted as described above. The
percentage of GCR binding activity then was calcu-
lated, with a 100% value being the GCR binding ac-
tivity obtained after incubation with the Sal. typhi
only. The specificity of the results was studied using
similar amounts of immune complexes incubated
with I ml of heat inactivated NHS.
The GCR binding activity then was determined
after incubation of normal human kidney sections
with the serum of 52 normal blood donors and of 49
patients presenting with various nephropathies.
Two groups of patients were selected on the basis of
the immunofluorescent microscopy data: The first
was composed of 5 patients with linear deposits of
immunoglobulins; the second was formed of 44 pa-
tients with granular deposits. Fifty-microliter sam-
ples of serum were tested, in duplicate, without pre-
liminary incubation with fresh NHS. Apart from
this modification, the GCR binding activity was de-
termined as described above.
Polyethylene glycol (PEG), with an average mo-
lecular weight of 6,000 daltons (Merck, Darmstadt,
West Germany), was dissolved in borate buffer
(ionic strength, 0.1; pH, 8.3 to 8.5) at concentra-
tions from 5 to 20% (weight per volume); 1 volume
of the positive" sera was mixed with I volume of
the various PEG solutions. The mixture was left at
4° C for 1 hour, then centrifuged at x2,000g for 20
mm. The supernatant was discarded, and the pre-
cipitate was washed twice at 4° C with the PEG so-
lution at the final concentration used in the mixture.
The last pellet was resuspended with VBS in one
fourth of the original volume. Samples of 50 were
then tested for their ability to reduce the GCR bind-
ing activity. Ultracentrifugations were performed
with a SW-65-Ti rotor in a Spinco L2-65B prepara-
tive ultracentrifuge (Beckman Instruments, Inc.).
Linear 10 to 40% (weight per volume) sucrose gradi-
ents were performed with a gradient mixer simulta-
neously in three tubes, in either borate buffer (pH,
8.3) or acetate buffer 0.1 M (pH, 3.8); 0.5 ml of
serum or of 5% PEG precipitate was layered, undi-
luted or diluted ten times in 0.15 M sodium chloride,
on 4.5-mI gradients, and centrifuged at 34,000 rpm
for 18 hours at 5° C. Serial fractions were collected,
and the OD values were measured at 276 m with a
0.3-mm flow cell (Uvicord, LKB-Produkter, Brom-
ma, Sweden). Normal lgG and 1gM (5 mg/mI)
were centrifuged in control tubes and were used,
respectively, as 7S and 19S reference markers. The
apparent S values were calculated according to the
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method of Martin and Ames [151. IgG concentration
in the gradient fractions was determined by quan-
titative radial immunodiffusion [161.
Rabbit antihuman IgG were coupled to CNBr-ac-
tivated Sepharose 4B (Pharmacia, Uppsala, Swe-
den) according to a previously described method
[171; the columns (3 ml) were washed with normal
rabbit serum to decrease the nonspecific binding
and then were equilibrated with borate buffer (pH,
8.3) at 40 C. Samples of 0.4 ml of 5% PEG precipi-
tates were applied to the columns. Serial fractions
of 0.2 ml were eluted with the borate buffer and
were tested as described above. CNBr-activated
Sepharose 4B coupled with bovine serum albumin
was used as control.
The Clq binding test was performed according to
the method of Zubler et al [10]. The serum samples
were drawn together with those for the measure-
ment of the GCR binding activity, from 28 out of the
49 patients mentioned above. Statistical evaluation
of the results was carried out by linear regression
analySiS.
Results
The C3 receptor was present in the three normal
human kidneys examined. Only the C3b-bearing
Sal. typhi were bound, with an uniform distribution
(Fig. 1). The influence of the number of bacteria, of
the incubation time, and of the incubation temper-
ature on the number of Sal. typhi bound to the
glomeruli is shown in Fig. 2. It was found that the
GCR binding activity increased proportionally to
the number of Sal. typhi used (Fig. 2A), depended
on the incubation time (Fig. 2B), and was higher at
37° C than it was at 4° C (Fig. 2C). These observa-
tionS demonstrated the dose dependency of the gb-
merular binding. Further, the effect of the com-
plement dilution on the GCR binding activity was
studied with several batches of fluoresceinated Sal.
typhi prepared with dilutions of fresh NHS ranging
from 1:1 to 1:64 [7]. Table 1 shows that the glomeru-
tar binding was complement-dose dependent. The
following experimental conditions were therefore
chosen to obtain a "normal" value of the GCR
binding activity located in the ascending part of the
dose-response curve: (a) the fluoresceinated Sal.
typhi were incubated with fresh NHS diluted two
times; (b) the Sal. typhi suspension was diluted to
obtain an OD of 1.8 at 540 ms and was incubated
with the kidney sections for 15 mm at 25° C. In
these conditions, the mean number of Sal. typhi
bound per glomerulus (± I SD) was 120 15 (Fig.
2D). This value has been considered as the 100%
value of the GCR binding activity. Control indicator
bacteria which did not contain C3b failed to bind to
the kidney tissue (Fig. 2D). No significant dif-
ferences in the "normal" GCR binding activity
were observed with the three different human kid-
Fig. 1. Light micrograph illustrating the binding of FITC-S. typhi bearing C'3b to the normal human glomnerular cells (original magnfica-
non x400): A in reference conditions, i.e., an 01) of the bacterial suspension of 1.8 at 540 p. an incubation time of 15 mm, and an
incubation temperature of 25° C (see Fig. 2) B in the presence of 50 pg of agg HGG contained in 1 ml of fresh NHS C in the presence of
/00 pg of agg. HGG contained in / ml of fresh NHS.
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Fig. 2. Influence of the number of FITC S. typhi-C3b used A, of
the incubation time B, and of the incubation temperature Con
the number of S.typhi bearing C3b bound per glomerulus. DBas-
ic and control experiments using S. typhi incubated with NHS,
with heat-inactivated NHS (NHS') or with Hank's balanced salt
solution (Hank's BSS). The mean number (± 1 SD) of S. typhi
bound per glomerulus in each experimental condition is in-
dicated.
neys examined, after otherwise identical experi-
mental conditions.
Finally, the reversibility of the binding has been
studied by adding a tenfold excess of unlabeled Sal.
typhi-C3b to the glomerular cells first incubated
with FITC Sal. typhi-C3b. The number of FITC
Sal. typhi bound per glomerulus was then reduced
by 75%. No binding was observed in the presence
of 20, 10, and 5 mrvi EDTA solutions.
The GCR binding activity was studied in the pres-
ence of increasing concentrations of agg HGG or of
DNA-anti-DNA immune complexes. The molecular
size of the complexes was higher than the 19S inter-
nal marker. The results are shown in Figs. 1 and 3.
The GCR binding activity was reduced by 60% in
the presence of 50 tg of agg HGG or of DNA-anti-
DNA complexes contained in 1 ml of fresh NHS.
Dilution of
human complement
Number of
hacteria°/glomerulus
1:1 124
1:2 116
1:4 86
1:8 30
1:16 13
1:32 7
1:64 5
a ODof the FITC-treated Sal. typhi, 1.8 at 540 mIa; incubation
time, 15 mm; incubation temperature, 25° C
No significant inhibition of the GCR binding activity
was obtained with similar concentration of agg.
HGG or of immune complexes incubated with 1 ml
of heat-inactivated NHS (Fig. 3).
In the presence of serum samples of 52 normal
blood donors, the mean percentage (± 1 SD) of GCR
binding activity was 100.0 12.5. Results of the
GCR binding activity in the presence of the serum
samples of 49 patients presenting with various
nephropathies are given in Table 2. It should be
stressed that (a) no patients presenting with glomer-
ulonephritis and linear deposits exhibited in their
serum a material reducing the GCR binding activity;
(b) such a material was found in the serum samples
>
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Table 1. Complement dose dependency of the binding of FITC-
treated Sal. typhi to the glomerular receptors
00 540 mp Time, rn/n
4°C 25°C 37°C Styphi +
Hank's NHS' NHS
BSS
100
80
60
40
----o-----o-
Immune complexes, pg/mi
Fig. 3. Inhibition of binding of FITC S. typhi-C3b to human gb-
merular cells by increasing concentrations of agg. HGG in-
cubated with fresh NHS (S—•) or with heat-inactivated NHS
(0—0), and by increasing concentrations of DNA-anti-DNA
complexes incubated with fresh NHS (A—A) or with heat-inacti-
vated NHS (A—A). The protein content was determined by the
method of Lowry et a! [12].
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Table 2. GCR binding activity after incubation of normal human
kidney sections with the serum of patients presenting with
glomerulonephritis and linear or granular immunoglobulin
deposits
Immunofluorescent
microscopy
No. of
patients
Inhibition of GCR
binding activity
(no. of inhibiting sera)
Linear deposits 5 0
Granular deposits 44 24
SO-gl samples of serum were incubated with the kidney sec-
tions prior to the adjunction of the FITC-treated Sal. typhi bear-
ing C3b (see "Methods").
of more than 50% of the patients presenting with
glomerulonephritis and granular deposits. Amongst
these "positive" patients, 6 out of 11 presented
with acute poststreptococcal glomerulonephritis, 9
out of 19 with membrano-proliferative glomerulone-
phritis, and 9 out of 14 with a lupus nephritis. The
percentage of inhibition of the GCR binding activity
among these patients ranged from 30 to 80%. Titra-
tion curves were performed after dilution of three
"positive" serum samples with NHS diluted ten
times with borate buffer. Examples of titration
curves are given in Fig. 4. In these cases, the titer of
the material reducing the GCR binding activity av-
eraged 1/16 to 1/32.
After precipitation by 5 and 10% PEG solutions
(final concentrations), it was found that most of the
inhibiting material was recovered in the PEG pre-
cipitates, thus suggesting that this material exhib-
ited a high molecular weight. To determine more
St
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Fig. 4. Titration of the material inhibiting the GCR binding activ-
ity. Titration curves obtained with the serum of a patient present-
ing with an endocapillary proliferative GN (0—0), amembrano-
proliferative GN (•—•), or a lupus nephritis (A—A) are repre-
sented.
precisely the molecular size of the inhibiting materi-
al, we performed gradient ultracentrifugations. Af-
ter ultra-centrifugation of the serum samples on su-
crose gradients, the maximum GCR inhibiting activ-
ity occurred in the fractions 2 to 4 (10 to 24S) (Fig.
5). No inhibiting material was obtained in similar
conditions from NHS.
To investigate the influence of acidification on the
inhibiting capacity of the gradient fractions, we per-
formed ultracentrifugations of three "positive" 5%
PEG precipitates in parallel runs on sucrose gra-
dients either at a pH of 8.3 or at a pH of 3.8. After
the run, the acidic fractions were neutralized, and
the GCR binding activity was determined on the
10 to 24S fractions of both gradients. Whereas a
material inhibiting the GCR binding activity was
found in fractions 2 to 4 of the gradient performed at
a pH of 8.3, no major inhibition of the GCR binding
activity was detected in any fraction obtained with
a-
E
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0
30
20
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Gradient fractions
Fig. 5. Inhibition of the GCR binding activity in the presence of
individual sucrose gradient fractions obtained after ultracentrif-
ugation of the serum of a patient presenting with lupus nephritis.
The GD pattern obtained with the serum diluted ten times in
0.9% sodium chloride, the position of the internal 7S and 19S
markers and the top of the gradient are indicated. The hatched
columns represent the percentage of inhibition of the GCR bind-
ing activity in individual gradient fractions.
19 S
100
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60
40
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40
Lupus
nephriti
11
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4
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the acid gradient (Fig. 6). Determination of the IgG
content of the gradient fractions by radial immuno-
diffusion [16] demonstrated that, in the former gra-
dient, IgG was located in fractions 2 to 5, whereas
in the latter, lgG was located in fractions 4 and 5.
lmmunoabsorption experiments were performed
with the inhibiting material concentrated in the 5%
PEG precipitate. Small columns of CNBr-Seph-
arose-4-B coupled with either rabbit antihuman IgG
or with bovine serum albumin were used. After elu-
tion with the borate buffer, it was found that the
material inhibiting the GCR binding activity was ab-
sorbed by the anti-IgG Sepharose columns, whereas
the effluent of the material passed through the bo-
vine serum albumin Sepharose columns still re-
duced the GCR binding activity. The absorbed ma-
terial was then eluted by acidic treatment 1171. After
neutralization, analysis of this material by radial im-
munodiffusion [161 demonstrated the presence of
IgG, Clq, C3, and C4.
The accuracy of measurement of the GCR bind-
ing activity was evaluated by calculating the coeffi-
cient of variation (CV) of results of duplicate deter-
minations around their means [181. In an assay in
which the percentage of inhibition of the GCR bind-
ing activity obtained with 50 d of the serum of a
patient presenting with glomerulonephritis and gran-
ular deposits was 65%, the CV was 8.6%, cal-
culated [18] on the basis of values ranging between
75 and 35% obtained from 16 samples of the same
serum. When aliquots of the same serum, frozen to-
gether, were tested on 10 separate days, the CV was
10.8%.
The Clq binding test was performed on EDTA-
treated plasma samples [101 from 28 out of the 49
patients mentioned above. The normal Clq binding
activity, determined with the serum of 62 normal
blood donors, was 5.8 1.9% (mean lsr). It has
been considered that patients presenting with at
least 9.6% of labeled Clq precipitated exhibited
positive results. Notwithstanding that the Clq bind-
ing test and the GCR binding assay exhibited com-
parable results in 78% of the cases, linear regression
analysis showed no significant correlation between
both methods (r = 0.28, NS).
Discussion
In this work, the presence of binding sites for C3
in the normal human glomerulus has been con-
firmed [2-8, 19]. Further, we have shown that the
number of Sal. typhi bearing C3b bound to the gb-
merular cells depends on the number of Sal. typhi
used, on the incubation time, and on the incubation
temperature. Since EDTA solutions strongly re-
duce the binding of Sal. typhi-C3b to glomeruli, it
seems reasonable to suggest that this binding is cal-
cium or magnesium dependent, or both. Sal. typhi
not containing C3b fail to bind to the glomerular
cells. This result demonstrates the specificity of the
binding.
The technical conditions selected for the binding
assay were such that about 120 bacterialglomerulus
were bound in the presence of normal sera. It
19S
+
04
0.2
Ig G
0.
a
pH 8.3
a0
40
C0
20
+5
Ig G
a(0
r— pH3.8(N
00
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0rC
0 T7I6!5 43 2 1
Top
Gradient fractions
Fig. 6. Inhibition of the GCR binding activity in the presence qf
individual sucrose gradient fractions separated after ultracentri-
fugation of the same PEG precipitate (5% final concentration) at
pH 8.3 or at pH 3.8. The OD patterns, the positions of the 7S
and 19S markers, the top of the gradient, and the presence of IgG
in the gradient fractions are indicated. The hatched columns rep-
resent the percentage of inhibition of the GCR binding activity in
the individual gradient fractions.
10
5
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seemed to us logical for the "normal" value of the
GCR binding activity to be located in the ascending
part of the dose-response curve, since the binding
of the Sal. typhi to the GCR is directly dose-depen-
dent (Fig. 2). We have found that agg. HGG or
DNA-anti-DNA complexes incubated with fresh
NHS strongly reduce the subsequent binding of Sal.
typhi bearing C3b to glomeruli. Since similar con-
centrations of agg. HGG or DNA-anti-DNA com-
plexes incubated with heat-inactivated NHS do not
modify the GCR binding capacity, it is likely that
this binding is not reduced in a nonspecific way.
The sensitivity of the test has been determined
with a material sedimenting in a high molecular
weight range (about 19S). In these conditions, the
lower concentration of immune complexes detect-
able is approximately 50 jsg/ml, which seems to in-
dicate a lower sensitivity than that of other tests de-
scribed for the detection of immune complexes [20-
23]. The determination of the GCR binding activity
in the presence of sera from patients presenting
with glomerulonephritis, however, proves inter-
esting, when compared with data reported, in com-
parable patient populations, with the Clq deviation
test [23], the Clq binding test [22], and the inhibi-
tion of uptake of radiolabeled aggregated IgG by
guinea pig peritoneal macrophage cells [21]. Indeed,
the serum samples of the normal blood donors and
of the patients presenting with glomerulonephritis
and linear deposits do not reduce the GCR binding
activity, whereas the serum samples of more than
50% of the patients presenting with GN and granu-
lar deposits contain a material reducing the GCR
binding activity.
We therefore suggest that, albeit less sensitive,
the simple method described here provides clinical
information at least comparable to that obtained
with more sensitive radioimmunoassays 120-231.
One cannot a priori rule out the possibility that non-
immune complex material may influence the re-
sults, and more particularly, free C3b. C3b, how-
ever, is degraded rapidly by C3b inactivators and
does not normally accumulate in the circulation
124]. Furthermore, the GCR-inhibiting material ex-
hibits some physiocochemical properties similar to
that of immune complexes [10, 221: It sediments in a
high molecular weight range on sucrose density gra-
dients (10 to 24S), and loses its ability to reduce the
GCR binding activity after acid dissociation, or af-
ter passage through an antilgG immunoabsorbant.
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